Members are advised of changes and updates to the Pharmaceutical Benefits Scheme. Several changes to the Pharmaceutical ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment ...

Panelists discuss decision-making in metastatic non–-small cell lung cancer (NSCLC) when molecular testing results are delayed, focusing on strategies to optimize treatment while awaiting results.

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.